FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Romano, S ^a   Staibano, S ^a   Greco, A ^a,b   Brunetti, A ^a,b   Nappo, G ^a   Ilardi, G ^a   Martinelli, R ^c   Sorrentino, A ^a   Di Pace, A ^a   Mascolo, M ^a   Bisogni, R ^a   Scalvenzi, M ^a   Alfano, B ^d   Romano, M F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d CNR   (Italy)

Author keywords

Cancer stem cell; Epithelial to mesenchymal transition; FKBP51; Melanoma; Metastasis

Indexed keywords

FK 506 BINDING PROTEIN; FK506 BINDING PROTEIN 51; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; INTERMEDIATE FILAMENT PROTEIN; NERVE PROTEIN; NESTIN; TACROLIMUS BINDING PROTEIN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; CELL MOTION; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MELANOMA; MICE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TACROLIMUS BINDING PROTEINS;

EID: 84876888439     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.109     Document Type: Article

References (40)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851–857; Review.
2. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010; 18: 510–523.
3. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2011; 18: 683–695.
4. Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 2012; 31: 828–841.
5. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004; 40: 2829–2836.
6. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400–1406.
7. Periyasamy S, Hinds Jr T, Shemshedini L, Shou W, Sanchez ER. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 2010; 29: 1691–1701.
8. Romano S, D’Angelillo A, Pacelli R, Staibano S, De Luna E, Bisogni R et al. Role of FK506 binding protein 51 (FKBP51) in the Control of Apoptosis of Irradiated Melanoma Cells. Cell Death Differ 2010; 17: 145–157.
9. Daudt DR, Yorio T. FKBP51 protects 661w cell culture from staurosporine-induced apoptosis. Mol Vis 2011; 17: 1172–1181.
10. Gallo LI, Lagadari M, Piwien-Pilipuk G, Galigniana MD. The Hsp90-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress. J Biol Chem 2011; 286: 30152–30160.
11. Romano S, Di Pace A, Sorrentino A, Bisogni R, Sivero L, Romano MF. FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem 2010; 10: 651–656; Review.
12. Dornan J, Taylor P, Walkinshaw MD. Structures of immunophilins and their ligand complexes. Curr Top Med Chem 2003; 3: 1392–1409; Review.
13. Somarelli JA, Lee SY, Skolnick J, Herrera RJ. Structure-based classification of 45 FK506-binding proteins. Proteins 2008; 72: 197–208.
14. Cioffi DL, Hubler TR, Scammell JG. Organization and function of the FKBP52 and FKBP51 genes. Curr Opin Pharmacol 2011; 11: 308–313.
15. Yao YL, Liang YC, Huang HH, Yang WM. FKBPs in chromatin modification and cancer. Curr Opin Pharmacol 2011; 1: 301–307.
16. Yeh WC, Li TK, Bierer BE, Yang WM. Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. Proc Natl Acad Sci USA 1995; 92: 11081–11085.
17. Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B. Identification of common pathways mediating differentiation of bone marrow-and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 2007; 25: 750–760.
18. Menicanin D, Bartold PM, Zannettino AC, Gronthos S. Genomic profiling of mesenchymal stem cells. Stem Cell Rev 2009; 5: 36–50.
19. Vittorioso P, Cowling R, Faure JD, Caboche M, Bellini C. Mutation in the Arabidopsis PASTICCINO1 gene, which encodes a new FK506-binding protein-like protein, has a dramatic effect on plant development. Mol Cell Biol 1998; 18: 3034–3043.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
21. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.
22. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265–273.
23. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–4751; Review.
24. Medrano MM. Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 2003; 22: 3123–3129.
25. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506–520.
26. Massagué J. TGF in cancer. Cell 2008; 134: 215–230.
27. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 2011; 30: 334–345.
28. Albini A, Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007; 2: 504–511.
29. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345–349.
30. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007; 43: 935–946.
31. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM et al. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 1992; 84: 165–174.
32. Nieto MA, Sargent MG, Wilkinson DG, Cooke J. Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 1994; 264: 835–839.
33. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155–166.
34. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927–939.
35. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell 1990; 60: 585–595.
36. Romano S, D’Angelillo A, Staibano S, Ilardi G, Romano MF. FK506-binding protein 51 is a possible novel tumoral marker. Cell Death Dis 2010; 15: e55.
37. Cesaro E, De Cegli R, Medugno L, Florio F, Grosso M, Lupo A et al. The Kruppel-like zinc finger protein ZNF224 recruits the arginine methyltransferase PRMT5 on the transcriptional repressor complex of the aldolase A gene. J Biol Chem 2009; 284: 32321–32330.
38. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65: 4320–4333.
39. Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010; 70: 697–708.
40. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2001; 71: 1474–1485.